This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Thomas Miller: Innovator in Plasma Kallikrein Inhibition
Introduction
Thomas Miller is a notable inventor based in Wakefield, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit plasma kallikrein.
Latest Patents
Miller holds a patent for "Inhibitors of plasma kallikrein and uses thereof." This patent describes compounds that inhibit pKal, a serine protease responsible for cleaving kininogen and generating bradykinin, a potent vasodilator and pro-inflammatory peptide. The invention aims to address painful and debilitating inflammatory attacks, such as edema. The patent also includes pharmaceutical compositions and kits that utilize these compounds, along with methods for treating pKal-related diseases and disorders.
Career Highlights
Thomas Miller is associated with Takeda Pharmaceutical Company Limited, where he applies his expertise in drug development and innovation. His work focuses on creating effective treatments for conditions related to plasma kallikrein activity.
Collaborations
Miller collaborates with esteemed colleagues, including Jeremy Mark Travins and Nikolaos Papaioannou, to advance research and development in the pharmaceutical sector.
Conclusion
Thomas Miller's innovative work in inhibiting plasma kallikrein showcases his commitment to improving healthcare through scientific advancements. His contributions are vital in the ongoing fight against inflammatory diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile